7 reports of this reaction
1.6% of all MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL reports
#16 most reported adverse reaction
HAEMATOCHEZIA is the #16 most commonly reported adverse reaction for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, manufactured by Haleon US Holdings LLC. There are 7 FDA adverse event reports linking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL to HAEMATOCHEZIA. This represents approximately 1.6% of all 436 adverse event reports for this drug.
Patients taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL who experience haematochezia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOCHEZIA is a less commonly reported adverse event for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, but still significant enough to appear in the safety profile.
In addition to haematochezia, the following adverse reactions have been reported for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL:
The following drugs have also been linked to haematochezia in FDA adverse event reports:
HAEMATOCHEZIA has been reported as an adverse event in 7 FDA reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOCHEZIA accounts for approximately 1.6% of all adverse event reports for MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, making it a notable side effect.
If you experience haematochezia while taking MINERAL OIL, PETROLATUM, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.